5/25/2025
Last update
5/25/2025
Reviewed By
Research Authors
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 21 Researches
7.4
USERS' SCORE
Good
Based on 3 Reviews
8.4
Supplement Facts
Serving Size: 1 Softgel
Serving Per Container: 30
Amount Per Serving
%DV
Calories
5
Total Fat
0.5 g
<1%¹
Total Omega-3 Fatty Acids
365 mg
DHA (Docosahexaenoic Acid)
350 mg
+
EPA (Eicosapentaenoic Acid)
15 mg
+
Top Medical Research Studies
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
8
We explored the impact of omega-3 fatty acid supplementation, particularly docosahexaenoic acid (DHA), on cardiovascular health through the Vitamin D and Omega-3 Trial (VITAL). This comprehensive study included nearly 26,000 older adults from the U.S., who received a daily dose of 840 mg of omega-3 fatty acids.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
7
Marine n-3 PUFAs and cardiovascular risk
We set out to explore how levels of marine n-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), relate to cardiovascular (CV) events and overall mortality, specifically in patients receiving hemodialysis. This prospective study tracked 336 patients over five years, monitoring their CV health and vital statistics.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
Most Useful Reviews
9
Excellent quality Omega
I've taken Omega from this company during pregnancy and lactation. The quality is excellent, and Omega is vital for cardiovascular disease, immunity, vision, and brain health. The dosage is good, and the pleasant taste makes the small capsules easy to swallow without causing a gag reflex. I highly recommend it.
7.5
Supports heart health
Supports women's heart health through Omega-3. It offers more than 100% of the recommended DHA dosage during pregnancy in a single easy-to-swallow softgel. With a delicious strawberry flavour, it ensures purity, potency, and value. This supplement contributes positively to cardiovascular disease.
7.5
DHA for health
This supplement helps maintain optimal DHA levels, crucial for cardiovascular disease, eye, and bone health. It also supports mood and improves breast milk quality, tailored specifically for pregnant and lactating women.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 21 Researches
7.4
- All Researches
9
We conducted a network meta-analysis to investigate the effects of docosahexaenoic acid, an omega-3 fatty acid, on heart failure management. By examining various randomized controlled trials, we aimed to understand how different dosages and durations of supplementation impact heart function.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
Our findings revealed that high-dose supplementation—ranging from 2000 to 4000 mg per day—over more than one year significantly improved heart function, particularly left ventricular ejection fraction and peak oxygen consumption. This indicates a promising role for docosahexaenoic acid in enhancing cardiovascular health in patients dealing with heart failure.
However, we also noted that lower doses and shorter treatment periods did not yield the same benefits. Importantly, the analysis showed no significant increase in dropout rates or all-cause mortality associated with omega-3 supplementation when compared to control groups.
Overall, the evidence suggests that long-term, high-dose docosahexaenoic acid supplementation can positively influence heart function without heightened risk. Future research should focus on more rigorous trials to further validate these findings and address any biases.
9
Icosapent ethyl reduces cardiovascular risks
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
9
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
8
We explored the impact of omega-3 fatty acid supplementation, particularly docosahexaenoic acid (DHA), on cardiovascular health through the Vitamin D and Omega-3 Trial (VITAL). This comprehensive study included nearly 26,000 older adults from the U.S., who received a daily dose of 840 mg of omega-3 fatty acids.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Excellent quality Omega
I've taken Omega from this company during pregnancy and lactation. The quality is excellent, and Omega is vital for cardiovascular disease, immunity, vision, and brain health. The dosage is good, and the pleasant taste makes the small capsules easy to swallow without causing a gag reflex. I highly recommend it.
7.5
Supports heart health
Supports women's heart health through Omega-3. It offers more than 100% of the recommended DHA dosage during pregnancy in a single easy-to-swallow softgel. With a delicious strawberry flavour, it ensures purity, potency, and value. This supplement contributes positively to cardiovascular disease.
7.5
DHA for health
This supplement helps maintain optimal DHA levels, crucial for cardiovascular disease, eye, and bone health. It also supports mood and improves breast milk quality, tailored specifically for pregnant and lactating women.
Frequently Asked Questions
7.5
Supports heart health
Supports women's heart health through Omega-3. It offers more than 100% of the recommended DHA dosage during pregnancy in a single easy-to-swallow softgel. With a delicious strawberry flavour, it ensures purity, potency, and value. This supplement contributes positively to cardiovascular disease.
7.5
DHA for health
This supplement helps maintain optimal DHA levels, crucial for cardiovascular disease, eye, and bone health. It also supports mood and improves breast milk quality, tailored specifically for pregnant and lactating women.
9
Excellent quality Omega
I've taken Omega from this company during pregnancy and lactation. The quality is excellent, and Omega is vital for cardiovascular disease, immunity, vision, and brain health. The dosage is good, and the pleasant taste makes the small capsules easy to swallow without causing a gag reflex. I highly recommend it.
8
We explored the impact of omega-3 fatty acid supplementation, particularly docosahexaenoic acid (DHA), on cardiovascular health through the Vitamin D and Omega-3 Trial (VITAL). This comprehensive study included nearly 26,000 older adults from the U.S., who received a daily dose of 840 mg of omega-3 fatty acids.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
Although we anticipated significant benefits, the results showed no overall reductions in major cardiovascular events, such as heart attacks and strokes, among the participants. However, our Bayesian analyses, which considered earlier research, suggested that omega-3 FA may still lower the risk of coronary events specifically.
While the evidence pointed towards limited effectiveness for stroke prevention, there seems to be a stronger case for incorporating omega-3 supplementation for reducing coronary-related issues. Overall, these findings enhance our understanding of how consistent omega-3 intake can be a valuable tool in primary prevention strategies for heart health.
7
Marine n-3 PUFAs and cardiovascular risk
We set out to explore how levels of marine n-3 polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), relate to cardiovascular (CV) events and overall mortality, specifically in patients receiving hemodialysis. This prospective study tracked 336 patients over five years, monitoring their CV health and vital statistics.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
Our findings revealed a significant connection: patients with lower levels of these essential fatty acids had a heightened risk of experiencing CV events and higher all-cause mortality. We found that those in the lower tertile of n-3 PUFA levels (below 5.06 weight percent) faced notably worse outcomes. Interestingly, those with moderate to high n-3 PUFA levels enjoyed a reduced risk of CV complications and even all-cause mortality, which indicates that increasing levels of EPA and DHA might be beneficial.
These insights suggest that maintaining healthy levels of marine n-3 PUFAs could be crucial for patients undergoing hemodialysis. We observed a potential threshold effect, indicating that risks of CV issues climb for those with n-3 PUFA levels below a certain point. This reinforces the importance of dietary omega-3 fatty acids for heart health, especially in vulnerable populations.
7
We explored how levels of omega-3 fatty acids, particularly docosahexaenoic acid (DHA), relate to heart health in patients with coronary artery disease (CAD) who are already on statin therapy. By measuring the serum levels of these fatty acids in 150 patients, we assessed their endothelial function through a test called flow-mediated dilation (FMD).
Our findings revealed a notable association between lower levels of DHA and impaired endothelial function, which is a key factor in the progression of atherosclerosis, a leading cause of heart disease. Among the participants, 65 who showed low endothelial function and low ratios of eicosapentaenoic acid (EPA) to arachidonic acid (AA) received EPA supplements for three months.
The results were promising, indicating that EPA therapy improved endothelial function significantly, especially in patients who also had high triglyceride levels. However, while we observed benefits from EPA treatment, the impact of DHA alone in the context of cardiovascular disease was not established as clearly, highlighting the need for further focused research.
Our findings revealed a notable association between lower levels of DHA and impaired endothelial function, which is a key factor in the progression of atherosclerosis, a leading cause of heart disease. Among the participants, 65 who showed low endothelial function and low ratios of eicosapentaenoic acid (EPA) to arachidonic acid (AA) received EPA supplements for three months.
The results were promising, indicating that EPA therapy improved endothelial function significantly, especially in patients who also had high triglyceride levels. However, while we observed benefits from EPA treatment, the impact of DHA alone in the context of cardiovascular disease was not established as clearly, highlighting the need for further focused research.
8
We explored the effects of docosahexaenoic acid (DHA) on cardiovascular disease (CVD) and how it may influence blood pressure (BP). DHA, an omega-3 fatty acid primarily found in fish oil, has piqued interest due to its potential benefits in managing heart health.
Recent findings indicate that DHA plays a significant role in reducing inflammation and improving vascular function. These properties are crucial since high blood pressure is a key risk factor for cardiovascular issues. Studies suggest that incorporating DHA into our diet could lead to lower BP levels, ultimately contributing to a lower risk of CVD.
However, while the evidence is promising, the precise effects of DHA can vary, and dietary sources should be approached thoughtfully to maximize benefits. By adjusting our intake of fatty acids like DHA, we can take proactive steps towards protecting our heart health and managing blood pressure effectively.
In summary, DHA shows great promise in supporting cardiovascular health, particularly concerning blood pressure management, highlighting the importance of dietary recommendations in preventing heart disease.
Recent findings indicate that DHA plays a significant role in reducing inflammation and improving vascular function. These properties are crucial since high blood pressure is a key risk factor for cardiovascular issues. Studies suggest that incorporating DHA into our diet could lead to lower BP levels, ultimately contributing to a lower risk of CVD.
However, while the evidence is promising, the precise effects of DHA can vary, and dietary sources should be approached thoughtfully to maximize benefits. By adjusting our intake of fatty acids like DHA, we can take proactive steps towards protecting our heart health and managing blood pressure effectively.
In summary, DHA shows great promise in supporting cardiovascular health, particularly concerning blood pressure management, highlighting the importance of dietary recommendations in preventing heart disease.
7
We explored how docosahexaenoic acid (DHA), a type of omega-3 fatty acid, influences platelet function—crucial for cardiovascular health—especially when combined with common antiplatelet medications. Our research involved testing DHA and another omega-3 fatty acid, eicosapentaenoic acid (EPA), alongside drugs like aspirin and ticagrelor to understand their effects on platelet aggregation in response to various triggers.
The results revealed that both DHA and EPA could inhibit platelet aggregation effectively. When combined with aspirin, DHA notably enhanced its ability to prevent platelet activation. Similarly, EPA boosted the effect of ticagrelor against platelet activation triggered by adenosine diphosphate. However, it's important to note that we found no significant improvement in the effects of other antiplatelet medications when used with these omega-3s.
Overall, while there were some positive interactions between omega-3 fatty acids and certain antiplatelet drugs, the combined treatment did not produce stronger results than the effects seen when each component was used individually. This suggests that while DHA can contribute to better platelet inhibition, the full advantages of DHA in cardiovascular care may still require further investigation.
The results revealed that both DHA and EPA could inhibit platelet aggregation effectively. When combined with aspirin, DHA notably enhanced its ability to prevent platelet activation. Similarly, EPA boosted the effect of ticagrelor against platelet activation triggered by adenosine diphosphate. However, it's important to note that we found no significant improvement in the effects of other antiplatelet medications when used with these omega-3s.
Overall, while there were some positive interactions between omega-3 fatty acids and certain antiplatelet drugs, the combined treatment did not produce stronger results than the effects seen when each component was used individually. This suggests that while DHA can contribute to better platelet inhibition, the full advantages of DHA in cardiovascular care may still require further investigation.
References
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. 10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. 10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. 10.3390/jcdd12020060
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. 10.1007/s11357-025-01544-6
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. 10.1016/j.advnut.2025.100366
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. 10.3390/jcm14010026
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. 10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. 10.1039/d4fo04961f
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. 10.1016/j.prostaglandins.2025.106948
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. 10.3390/nu16233995
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. 10.1016/j.pcad.2024.11.003
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. 10.1016/j.plefa.2024.102655
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. 10.3389/fnut.2024.1423228
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. 10.1093/eurjpc/zwae315
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. 10.3390/ijms251810136
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. 10.1161/JAHA.124.038656
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. 10.1007/s40261-024-01417-4
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. 10.7759/cureus.73417
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. 10.3390/nu16213614
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. 10.1038/s44319-024-00271-x
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. 10.1016/j.athplu.2024.09.002
